PTHLH and prostate carcinoma: In a mouse model, overexpression of PTHrP (1–87) or PTHrP (1–173) in the DU-145 prostate cancer cell line significantly increased bone metastasis and caused more severe osteolytic/osteoblastic-mixed lesions in an intrafemoral injection.